SCHEMBL1945684

SCHEMBL1945684

O=C(Nc1ccc2c(c1)CCN(C(=O)NS(=O)(=O)c1ccccc1)CC2)NS(=O)(=O)c1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNA1 Q09470 10/20 0.80
KCNAB1 Q14722 10/20 0.80
NLRP3 Q96P20 1/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTR6 P50406 1/20 0.45
CA12 O43570 3/20 0.45
CA9 Q16790 3/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1945005 0.94 KCNA1 (0.92) KCNA1KCNAB1NLRP3NPC1RAB9A
SCHEMBL1944620 0.89 KCNA1 (0.80) KCNA1KCNAB1NPC1RAB9AMEN1
SCHEMBL1945000 0.89 KCNA1 (1.00) KCNA1KCNAB1MEN1KMT2ALMNA
SCHEMBL12540222 0.89 KCNA1 (0.64) KCNA1KCNAB1NPC1RAB9AMEN1
SCHEMBL1945507 0.89 KCNA1 (1.00) KCNA1KCNAB1NLRP3NPC1RAB9A
SCHEMBL1947591 0.88 KCNA1 (1.00) KCNA1KCNAB1NLRP3NPC1RAB9A
SCHEMBL1948073 0.86 KCNA1 (1.00) KCNA1KCNAB1NLRP3MEN1KMT2A
SCHEMBL1945019 0.86 KCNA1 (1.00) KCNA1KCNAB1NPC1RAB9ALMNA
SCHEMBL1946635 0.84 KCNA1 (0.70) KCNA1KCNAB1NPC1RAB9AMEN1
SCHEMBL12563951 0.83 KCNA1 (0.71) KCNA1KCNAB1MEN1KMT2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US claimed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US claimed
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US disclosed
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases LECTUS THERAPEUTICS LIMITED (GB) 2011-06-02 US disclosed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed
US-20090318423-A1 Ion Channel Modulators & Uses Thereof LECTUS THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed
EP-2069309-A1 ION CHANNEL MODULATORS&USES THEREOF Lectus Therapeutics Limited (GB) 2009-06-17 EP disclosed
WO-2008149163-A2 POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF LECTUS THERAPEUTICS LIMITED (GB) 2008-12-11 WO disclosed
WO-2008038053-A1 ION CHANNEL MODULATORS & USES THEREOF LECTUS THERAPEUTICS LIMITED (GB) 2008-04-03 WO disclosed
WO-2008038053-A1 ION CHANNEL MODULATORS & USES THEREOF LECTUS THERAPEUTICS LIMITED (GB) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318423-A1 Ion Channel Modulators & Uses Thereof KCNH3, KCNN3, KCNH2 KCNA1 26/4885KCNAB1 40/4885NLRP3 1018/4885
US-20110130383-A1 Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases HCAR2, HCAR1, SCN7A KCNA1 167/4885KCNAB1 98/4885NLRP3 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.